직장암에 수술 전 항암화학방사선 동시 병용요법 후 종양의 병리학적 반응에 영향을 주는 임상적 예측 인자 = Clinical Factors Predicting the Pathologic Tumor Response after Preoperative Concurrent Chemoradiotherapy for Rectal Cancer

국문 초록 (Abstract)

목 적: 직장암에 수술 전 항암화학요법과 방사선치료를 동시에 병용시행한 후 완치절제술 후 병리학적 완전관해율
과 종양 병기 하향률에 영향을 주는 예측인자를 후향적으로 분석하여 환자에 따른 맞춤치료의 가능성을 알기 위하
여 본 연구를 시도하였다. 대상 및 방법: 2000년 5월부터 2008년 3월까지 국소적으로 진행된 직장암으로 진단받고 원격전이가 없는 환자39명을 대상으로 수술 전 항암화학요법과 골반강에 방사선치료 50.4 Gy (45∼59.4 Gy)를 시행한 후 완치적 수술후 절제된 조직을 병리학적으로 관찰하여 완전관해율과 종양 및 림프절의 병기하향률을 측정하였다. 항암화학요법은 39명 중 38명은 방사선치료 1주와 5주에 각각 1주간 5-fluorouracil과 leucovorin을 연속적으로 정맥 주입하였
으며 1명은 방사선치료기간 중 하루에 2회 capecitabine를 복용하였다. 결 과: 병리학적 완전관해를 보인 환자는 39명 중 12명(31%), 종양-병기하향을 보인 환자는 24명(63%)이었으며 임상적으로 림프절이 양성인 환자 28명 중 12명은(43%) 병리학적으로 하향되었으며 2명은 임상적으로 림프절이 음성이었으나 병리학적으로 양성을 보였다. 단변량분석에 의하면 종양의 둘레범위가 직장의 50% 미만(p=0.031),종양의 길이가 5 cm 미만(p=0.004), 치료 후 CEA 수치가 3.0 mg/mL 이하(p=0.015)인 환자에서 병리학적 완전관해율이 높았다. 또한 선암(p=0.045), 방사선량이 50 Gy 이상(p=0.021)인 환자에서 병기-하향률이 높았고, 방사선 치료 기간이 42일 이하인(p=0.018) 환자에서 림프절-병기하향률이 높았다. 다변량분석에 의하면 종양의 둘레범위가 50% 미만(HR 0.150; p=0.028), 종양의 길이가 5 cm 미만인(HR 0.084; p=0.005) 환자에서 통계학적으로 유의하게 병리학적 완전관해율이 높았으며, 방사선량이 50 Gy 이상 높은 경우(HR 0.115; p=0.025) 종양-병기하향률이높았고 방사선치료 기간이 42일 이하인(HR 0.028; p=0.010) 경우 림프절-병기하향률이 높았다. 결 론: 병리학적 완전관해에 영향을 주는 예측인자는 종양의 둘레범위와 종양의 길이이었으며, 종양-병리하향에 영향을 주는 예측인자는 방사선량, 림프절-병기하향에 영향을 주는 예측인자는 방사선치료 기간이었다. 이러한 예측인자를 파악함으로써 환자의 치료결과를 예측할 수 있으며 위험인자가 있는 환자에 좀 더 적극적인 치료계획을 설정하는 데 도움이 될 것으로 생각한다.

다국어 초록 (Multilingual Abstract)

Purpose: The objective of this retrospective study was to identify predictive factors for the complete pathologic response and tumor downstaging after preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. Materials and Methods: Between the years 2000 and 2008, 39 patients with newly diagnosed rectal cancer without prior evidence of distant metastasis received preoperative concurrent chemoradiotherapy followed by surgery. The median radiation dose was 50.4 Gy (range, 45∼59.4 Gy). Thirty-eight patients received concurrent infusional 5-fluorouracil and leucovorin, while one patient received oral capecitabine twice daily during radiotherapy. Results: A complete pathologic response (CR) was demonstrated in 12 of 39 patients (31%), while T-downstaging was observed in 24 of 39 patients (63%). N-downstaging was observed in 18 of 28 patients
(64%), with a positive node in the CT scan or ultrasound. Two patients with clinical negative nodes were
observed in surgical specimens. The results from a univariate analysis indicated that the tumor circumferential
extent was less than 50% (p=0.031). Moreover, the length of the tumor was less than 5 cm (p=0.004), while
the post-treatment carcinoembryonic antigen (CEA) levels were less than or equal to 3.0 ng/mL (p=0.015) and
were significantly associated with high pathologic CR rates. The univariate analysis also indicated that the
adenocarcinoma (p=0.045) and radiation dose greater than or equal to 50 Gy (p=0.021) were significantly
associated with high T-downstaging, while a radiotherapy duration of less than or equal to 42 days (p=0.018)
was significantly associated with N-downstaging. The results from the multivariate analysis indicated that the
lesser circumferential extent of the tumor (hazard ratio [HR], 0.150; p=0.028) and shorter tumor length (HR,
0.084; p=0.005) independently predicted a higher pathologic CR. The multivariate analysis also indicated that a
higher radiation dose was significantly associated with higher T-downstaging (HR, 0.115; p=0.025), while the
shorter duration of radiotherapy was significantly associated with higher N-downstaging (HR, 0.028; p=0.010).
Conclusion: The circumferential extent of the tumor and its length was a predictor for the pathologic CR, while
radiation dose and duration of radiotherapy were predictors for tumor downstaging. Hence, these factors may
be used to predict outcomes for patients and to develop further treatment guidelines for high-risk patients.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과
• 고안 및 결론

참고문헌 (Reference)

1 Lowe SW, "p53 status and efficacy of cancer therapy in vivo" 807-810, 1994

2 Lowe SW, "p53 status and efficacy of cancer therapy in vivo" 807-810, 1994

3 Esposito G, "p27Kip1 is associated with tumor response to preoperative chemoradiotherapy in rectal cancer" 8 : 311-338, 2001

4 Willett CG, "Tumor proliferation in rectal cancer following preoperative irradiation" 13 : 1417-1424, 1995

5 Janjan NA, "Tumor downstaging and sphincter preservation in locally advanced rectal cancer: the M.D. Anderson Cancer Center Experience" 44 : 1007-1038, 1999

6 Kaminsky-Forrett MC, "Tlevel downstaging and complete pathologic regression afterpreoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival" 45 : 815-903, 2002

7 Vecchio FM, "The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer" 62 : 752-760, 2005

8 Theodoropoulos G, "T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival" 45 : 895-903, 2002

9 Minsky BD, "Sphincter preservation with preoperative radiation therapy and coloanal anastomosis" 31 : 553-559, 1995

10 Park YA, "Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer" 93 : 145-150, 2006

11 Choi SG, "Results of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer" 25 : 34-42, 2007

12 Moore HG, "Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection" 47 : 279-286, 2004

13 Stockholm Colorectal Cancer Study Group, "Randomized study on preoperative radiotherapy in rectal carcinoma" 3 : 423-430, 1996

14 Brugarolas J, "Radiationinduced cell cycle arrest compromised by p21 deficiency" 552-557, 1995

15 Gastrointestinal Tumor Study Group, "Radiation therapy and fluorouracial with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum" 10 : 549-557, 1992

16 Gastrointestinal Tumor Study Group, "Prolongation of the disease- free interval in surgically treated rectal carcinoma" 1465-1472, 1985

17 Losi L, "Prognostic value of Dworak grade of regression (GR) in patient with rectal carcinoma treated properative radiochemotherapy" 21 : 645-651, 2006

18 RÖodel C, "Prognostic significance of tumor regression after preoperative chemoradio therapy for rectal cancer" 23 : 8688-8696, 2005

19 Janjan NA, "Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer" 51 : 153-160, 1995

20 Kaminsky-Forett MC, "Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer" 42 : 935-941, 1998

21 Gerad JP, "Preoperatuve radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancer: results of FFCD 9203" 24 : 4620-4625, 2006

22 Sauer R, "Preoperative versus postoperative chemoradiotherapy for rectal cancer" 1731-1740, 2004

23 Wheeler JM, "Preoperative radiotherapy for rectal cancer: implications for surgeons, pathologists and radiologists" 86 : 1108-1120, 1999

24 Frykholm GJ, "Preoperative or postoperative irradiation in adenocarcinoma of the rectum with final treatment results of a randomized trial and an evaluation of late secondary effects" 36 : 564-572, 1993

25 Gerad JP, "Preoperative concurrent chemoradiatiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R004 phase II trial" 21 : 1119-1124, 2003

26 Chan A, "Preoperative concurrent 5-fluorouracil infusion, mitomycin-C and pelvic radiation therapy in tethered and fixed rectal carcinoma" 25 : 791-799, 1993

27 Mohiuddin M, "Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response" 46 : 883-888, 2000

28 Grann A, "Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin and concurrent radiation therapy for clinically resectalbe T3 rectal cancer" 40 : 515-522, 1997

29 Das P, "Predictors of tumor response and downstaging in patients who received preoperative chemoradiation for rectal cancer" 109 : 1750-1755, 2007

30 Dworak O, "Pathological features of rectal cancer after preoperative radiochemotherapy" 12 : 19-23, 1997

31 Ahmed NR, "Pathologic complete response predicts long-term survival following preoperative radiation therapy for rectal cancer" 39 : 284-, 1997

32 Francois Y, "Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial" 17 : 2396-2402, 1999

33 O’Connell MJ, "Improving adjuvant therapy for rectal cancer by combining protracted- infusion fluorouracil with radiation therapy after curative surgery" 502-507, 1994

34 Swedish Rectal Cancer Trial, "Improved survival with preoperative radiotherapy in resectable rectal cancer" 980-987, 199

35 Bouzourene H, "Importance of tumor regression assessment in predicting the outcome in patient with locally advanced rectal carcinoma who are treated with preoperative radiotherapy" 94 : 1121-1130, 2002

36 Boulis-Wassif S, "Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil followed by radical surgery. Trial of the europena orgniazation on resrarch and treatment of cancer gastrointestinal tract cancer cooperative group" 53 : 1811-1818, 1984

37 Giratt J, "Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patient treated with preoperative radiotherapy" 54 : 1460-1465, 2002

38 Bosset JF, "Enhanced tumorcidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921" 23 : 5620-5627, 2005

39 Ghadimi BM, "Effectiveness of gene expression profiling for response prediction of rectal adenocarcinoma to preoperative chemoradiotherapy" 23 : 1826-1838, 2005

40 Krook JE, "Effective surgical adjuvant therapy for high-risk rectal carcinoma" 709-715, 1991

41 Rau B, "Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy" 21 : 3391-3401, 2003

42 John M, "Dose acceleration in chemoradiation for anal cancer: preliminary results of RTOG 9208" 2 : 205-211, 1996

43 Valentini V, "Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients" 53 : 664-674, 2002

44 Smith FM, "Cox-2 overexpression in pretreatment biopsies predicts response of rectal cancer to neoadjuvant radiochemotherapy" 64 : 466-472, 2006

45 Pucciarelli S, "Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome" 47 : 1798-1807, 2004

46 Minsky BD, "Combined modality therapy for rectal cancer; decreased acute toxicity with the preoperative approach" 10 : 1218-1224, 1992

47 Moertel C, "Combined 5-FU and radiation therapy as a surgical adjuvant for poor prognostic gastric cancer" 2 : 1249-1254, 1984

48 Yoon SM, "Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer" 69 : 1167-1172, 2007

49 Bosset JF, "Chemotherapy with preoperative radiotherapy in rectal cancer" 1114-1123, 2006

50 Sanghera P, "Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response" 20 : 176-183, 2008

51 Colorectal Cancer Collaborative Group, "Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomized trials" 1291-1304, 2001

52 Garcia-Aguilar J, "A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patient treated by mesorectal excision" 46 : 298-304, 2003